Latest HCC Treatment Guidelines
For advanced HCC with preserved liver function (Child-Pugh A) and good performance status (ECOG 0-1), atezolizumab plus bevacizumab is now the first-line standard of care, demonstrating superior survival compared to sorafenib. 1
Treatment by Disease Stage
Very Early and Early Stage HCC
Curative Intent Options:
- Surgical resection is the treatment of choice for single HCC in patients with preserved liver function 2
- Liver transplantation should be considered for patients meeting criteria, with neoadjuvant locoregional therapy recommended while on the waiting list to prevent dropout from disease progression 3
- Thermal ablation (radiofrequency or microwave - both equally effective) is first-line treatment for:
- Percutaneous ethanol injection can be used for solitary HCC <2 cm when thermal ablation is not technically feasible 3
Intermediate Stage HCC
Locoregional Therapy:
- Transarterial chemoembolization (TACE) or transarterial embolization (TAE) is standard of care 3
- Best candidates have:
- Limited tumor burden (solitary nodule <7 cm or fewer than 4 tumors)
- Preserved liver function (Child-Pugh A or B7 without ascites)
- Good performance status (ECOG <2) 3
Critical contraindications to TACE/TAE:
- Decompensated liver disease
- Advanced kidney dysfunction
- Macroscopic vascular invasion
- Extrahepatic spread 3
Important caveat: For large-volume intrahepatic disease, despite being classified as intermediate stage, systemic therapy or selective internal radiation therapy (SIRT) may be more appropriate than TACE/TAE 3
Advanced Stage HCC
First-Line Systemic Therapy:
The combination of atezolizumab plus bevacizumab is the preferred first-line treatment based on the IMbrave150 trial, which demonstrated:
- Superior overall survival vs. sorafenib (median 19.2 vs. 13.4 months; HR 0.58)
- Superior progression-free survival (HR 0.59)
- Higher response rate (27.3% vs. 11.9%) 1
Pre-treatment requirements for atezolizumab/bevacizumab:
- Patients with portal hypertension must have upper GI endoscopy within 6 months
- Varices must be adequately treated before starting therapy 3
Alternative First-Line Options:
When atezolizumab/bevacizumab is contraindicated or declined:
- Sorafenib or lenvatinib (oral alternatives) 3
- Durvalumab plus tremelimumab (STRIDE regimen) demonstrated superior OS vs. sorafenib (median 16.43 vs. 13.77 months; HR 0.78) in the HIMALAYA trial 1
Key Treatment Principles Across All Stages
Multidisciplinary team discussion is essential for treatment decisions, considering:
- Tumor characteristics (size, number, location)
- Liver function (Child-Pugh score, portal hypertension)
- Performance status
- Patient preferences
- Treatment availability 1, 3
Important pitfalls to avoid:
- Do not combine TACE with multikinase inhibitors 3
- Insufficient evidence currently to recommend TACE combined with immune checkpoint inhibitors 3
- Biomarkers are not currently useful in systemic therapy decision-making 1
- Avoid direct cross-trial comparisons when selecting between systemic therapies - focus on patient profile and contraindications 1
Emerging Considerations
Adjuvant therapy: Atezolizumab plus bevacizumab may improve recurrence-free survival after ablation, but longer-term follow-up is required before routine recommendation 3
Stereotactic radiotherapy is an option for tumors in patients unsuitable for surgery or conventional ablative techniques 3